Home > Press > CombiMatrix Corporation Retires All Remaining Convertible Debt
CombiMatrix Corporation (Nasdaq:CBMX) announced today that it has fully repaid the secured convertible debenture held by YA Global Investments, L.P., which had an original principal amount of $10.0 million.
CombiMatrix Corporation Retires All Remaining Convertible Debt
Mukilteo, WA | Posted on March 3rd, 2010
As a result of retiring this debt, the potentially dilutive reserve of approximately 1.1 million shares of common stock that could have been issued from conversion of the remaining debt was also retired.
"Retiring this debt strengthens our overall financial position and better positions CombiMatrix for future growth as well as attaining our strategic objectives," stated Scott Burell, Chief Financial Officer and Treasurer of CombiMatrix Corporation.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our periodic and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
CombiMatrix Corporation is a diversified biotechnology business that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology and defense and homeland security markets, as well as in other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce user-defined, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs.
Combimatrix Molecular Diagnostics, Inc. ("CMDX"), our wholly owned subsidiary located in Irvine, California, operates as a diagnostics reference laboratory that provides genetic diagnostics services to physicians, hospitals and clinics. CMDX provides its services through the use of arrays that utilize bacterial artificial chromosomes ("BACs") that enable genetic analysis. This type of technology is generally known as aCGH (or, array-Comparative Genomic Hybridization), and enables the analysis of gross genetic anomalies. CMDX also sells BAC array slides to labs outside the U.S. In addition, CMDX utilizes other non-proprietary technologies and products to augment its laboratory services in aCGH as well as ancillary services.
Leuchemix Inc. ("Leuchemix"), a minority owned subsidiary, is developing a series of compounds to address a number of oncology-related diseases. Leuchemix's first compound has entered initial clinical trials in the United Kingdom.
Additional information about CombiMatrix Corporation is available at www.combimatrix.com or by calling 1-800-985-CBMX (2269). Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.
For more information, please click here
Amit Kumar, Ph.D., President & CEO
Fax (425) 493-2010
Investor Relations Contact:
Jeffrey Stanlis, Partner
Copyright © CombiMatrix
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
News and information
Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014
Brookhaven Lab Launches Computational Science Initiative:Leveraging computational science expertise and investments across the Laboratory to tackle "big data" challenges October 22nd, 2014
Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014
NIST offers electronics industry 2 ways to snoop on self-organizing molecules October 22nd, 2014
NanoTechnology for Defense (NT4D) October 22nd, 2014
Mechanism behind nature's sparkles revealed October 22nd, 2014
TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014
Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014
Aspen Aerogels, Inc. Schedules Third Quarter 2014 Earnings Release and Conference Call for November 6, 2014 October 17th, 2014
Nanometrics to Announce Third Quarter Financial Results on October 28, 2014 October 8th, 2014
Harris & Harris Group Letter to Shareholders on Website August 19th, 2014
Arrowhead Reports Fiscal 2014 Third Quarter Financial Results and Provides Update on ARC-520 August 12th, 2014